Q4 2025 · 13F-HR
ORBIMED ADVISORS LLCholdings as filed
Filed 2026-02-17 · accession 0001172661-26-001119
$4.90B
Reported value
107
Positions
2025-12-31
Period end
The Brief · ORBIMED ADVISORS LLC · Q4 2025
AI · grounded in 13F
ORBIMED ADVISORS LLC closed its position in SIBN for a reduction of $37.96M. The fund also exited positions in SCPH and ITGR, reducing holdings by $34.36M and $29.97M respectively. On the buy side, the fund established new positions in BMY for $41.8M and ELV for $34.74M. Additionally, the fund increased its stake in EW by 18.34%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $385.1M | 7.86% | 15,518,492 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $323.7M | 6.61% | 301,200 | Common | NONE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $230.7M | 4.71% | 2,419,300 | Common | NONE |
| P8696W104 | SVA | SINOVAC BIOTECH LTD | $184.5M | 3.77% | 2,718,735 | Common | NONE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $157.1M | 3.21% | 1,842,900 | Common | NONE |
| 91678A107 | UPB | UPSTREAM BIO INC | $154.6M | 3.16% | 5,693,589 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $149.2M | 3.04% | 263,400 | Common | NONE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $146.5M | 2.99% | 3,561,655 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $124.1M | 2.53% | 3,935,203 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $122.8M | 2.51% | 146,000 | Common | NONE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $122.6M | 2.50% | 7,959,538 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $114.8M | 2.34% | 288,800 | Common | NONE |
| 863667101 | SYK | STRYKER CORPORATION | $114.2M | 2.33% | 325,000 | Common | NONE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $96.6M | 1.97% | 8,288,510 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $87.0M | 1.78% | 2,153,300 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $84.8M | 1.73% | 1,067,550 | Common | SOLE |
| 142152107 | CAI | CARIS LIFE SCIENCES INC | $84.1M | 1.72% | 3,116,011 | Common | NONE |
| 632307104 | NTRA | NATERA INC | $83.8M | 1.71% | 365,800 | Common | NONE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $81.7M | 1.67% | 15,219,994 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $80.8M | 1.65% | 1,161,803 | Common | NONE |
| 235851102 | DHR | DANAHER CORPORATION | $68.6M | 1.40% | 299,800 | Common | NONE |
| 156944100 | CGON | CG ONCOLOGY INC | $63.0M | 1.29% | 1,516,550 | Common | NONE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $61.0M | 1.25% | 2,429,868 | Common | NONE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $60.9M | 1.24% | 3,027,328 | Common | SOLE |
| 125523100 | CI | THE CIGNA GROUP | $56.4M | 1.15% | 205,000 | Common | NONE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $55.6M | 1.14% | 1,642,891 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $55.2M | 1.13% | 7,165,006 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $51.3M | 1.05% | 105,200 | Common | NONE |
| 00370M103 | ABVX | ABIVAX SA | $49.6M | 1.01% | 367,900 | Common | NONE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $47.5M | 0.97% | 2,190,907 | Common | NONE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $46.5M | 0.95% | 999,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $46.2M | 0.94% | 253,121 | Common | NONE |
| 30233G209 | EYPT | EYEPOINT INC | $45.1M | 0.92% | 2,468,314 | Common | NONE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $44.7M | 0.91% | 619,530 | Common | NONE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $44.6M | 0.91% | 314,240 | Common | NONE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $43.1M | 0.88% | 2,202,184 | Common | NONE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $41.8M | 0.85% | 775,000 | Common | NONE |
| 717081103 | PFE | PFIZER INC | $41.2M | 0.84% | 1,652,900 | Common | NONE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $39.9M | 0.82% | 3,190,700 | Common | NONE |
| 641288105 | NPCE | NEUROPACE INC | $37.2M | 0.76% | 2,406,335 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $36.7M | 0.75% | 171,977 | Common | NONE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $35.7M | 0.73% | 351,716 | Common | NONE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $35.6M | 0.73% | 980,400 | Common | NONE |
| 036752103 | ELV | ELEVANCE HEALTH INC FORMERLY | $34.7M | 0.71% | 99,100 | Common | NONE |
| 34962G208 | FBRX | FORTE BIOSCIENCES INC | $32.6M | 0.67% | 1,196,955 | Common | SOLE |
| 74065P101 | PRLD | PRELUDE THERAPEUTICS INC | $31.6M | 0.65% | 10,909,256 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $31.4M | 0.64% | 3,840,500 | Common | NONE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $29.8M | 0.61% | 3,641,756 | Common | NONE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $29.5M | 0.60% | 119,800 | Common | NONE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $27.9M | 0.57% | 94,500 | Common | NONE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $27.0M | 0.55% | 1,954,426 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $26.9M | 0.55% | 46,500 | Common | NONE |
| 116794108 | BRKR | BRUKER CORP | $26.2M | 0.53% | 555,789 | Common | NONE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $25.7M | 0.52% | 239,800 | Common | NONE |
| 82024L103 | STTK | SHATTUCK LABS INC | $23.0M | 0.47% | 6,306,127 | Common | SOLE |
| 29664W105 | ESPR | ESPERION THERAPEUTICS INC NE | $22.1M | 0.45% | 5,965,498 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $21.6M | 0.44% | 1,187,300 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $21.1M | 0.43% | 2,125,000 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $20.6M | 0.42% | 5,822,854 | Common | NONE |
| M96088105 | URGN | UROGEN PHARMA LTD | $20.5M | 0.42% | 875,487 | Common | NONE |
| 000000000 | — | PRELUDE THERAPEUTICS INC | $20.1M | 0.41% | 6,210,899 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $20.0M | 0.41% | 447,200 | Common | NONE |
| 10950A106 | BTSG | BRIGHTSPRING HEALTH SVCS INC | $18.3M | 0.37% | 488,500 | Common | NONE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $17.9M | 0.37% | 353,500 | Common | NONE |
| N90064101 | QURE | UNIQURE NV | $17.6M | 0.36% | 737,400 | Common | NONE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $16.4M | 0.34% | 1,226,700 | Common | NONE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $16.4M | 0.33% | 804,212 | Common | SOLE |
| 14280C105 | CARL | CARLSMED INC | $15.5M | 0.32% | 1,252,600 | Common | NONE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $15.0M | 0.31% | 3,525,650 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $14.4M | 0.29% | 2,380,715 | Common | NONE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $13.6M | 0.28% | 1,741,800 | Common | NONE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $13.2M | 0.27% | 371,000 | Common | NONE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $13.0M | 0.27% | 1,597,287 | Common | NONE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $12.8M | 0.26% | 150,000 | CALL | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $12.6M | 0.26% | 154,400 | Common | NONE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $12.6M | 0.26% | 2,610,600 | Common | NONE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $12.0M | 0.24% | 574,600 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $10.8M | 0.22% | 1,102,730 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $10.5M | 0.21% | 790,901 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $10.4M | 0.21% | 729,900 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $10.1M | 0.21% | 4,166,000 | Common | SOLE |
| 007002207 | ACET | ADICET BIO INC | $8.7M | 0.18% | 1,027,944 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $8.6M | 0.18% | 3,322,488 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $8.5M | 0.17% | 85,664 | Common | NONE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $8.2M | 0.17% | 531,163 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $7.7M | 0.16% | 187,199 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC | $7.5M | 0.15% | 2,252,987 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $6.2M | 0.13% | 4,975,291 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $6.2M | 0.13% | 382,400 | Common | NONE |
| N69605108 | PHVS | PHARVARIS N V | $5.7M | 0.12% | 205,400 | Common | NONE |
| 45779A846 | NSPR | INSPIREMD INC | $5.6M | 0.11% | 3,133,405 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $4.4M | 0.09% | 25,400 | Common | NONE |
| 696389402 | PALI | PALISADE BIO INC | $4.4M | 0.09% | 1,871,420 | Common | NONE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $3.5M | 0.07% | 209,100 | Common | NONE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $2.8M | 0.06% | 270,006 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $2.7M | 0.05% | 1,404,902 | Common | NONE |
| 45175G207 | IMA | IMAGENEBIO INC | $2.6M | 0.05% | 378,556 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $2.2M | 0.05% | 125,000 | Common | NONE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $2.1M | 0.04% | 25,900 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $2.0M | 0.04% | 3,060,000 | Common | NONE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $1.9M | 0.04% | 157,300 | Common | NONE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $1.9M | 0.04% | 21,700 | Common | NONE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $1.8M | 0.04% | 23,200 | Common | NONE |
| 19240QAA0 | COGT 1.625 11/15/31 | COGENT BIOSCIENCES INC | $1.2M | 0.02% | 1,000,000 | Common | NONE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $952,000 | 0.02% | 56,000 | Common | NONE |
| 68232V884 | TRAW | TRAWS PHARMA INC | $684,250 | 0.01% | 605,531 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $29,918 | 0.00% | 45,200 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.